384/2007 Coll.
DECREE


Dated December 19, 2007

A list of reference groups

Change: 114/2009 Coll.

Change: 386/2011 Coll.

Ministry of Health, pursuant to § 39c paragraph. 1 of Law no.
48/1997 Coll., On public health insurance and amending and supplementing
some related laws, as amended by Act no. 261/2007 Coll .:

§ 1

List of groups of medicines in principle, therapeutically interchangeable with
similar or close to efficacy and safety with similar clinical
utilization (hereinafter referred to as the "reference group") is contained in the annex to this decree
.

§ 2

This decree comes into force on 1 January 2008.
Minister
:

MD. Julínek, MBA vr
Notes



List of reference groups ----------------------------------------- -------------------------- ---------------------------------------------------------------------------------------------------------
Number of therapeutic group reference number Referenčnískupina ^ *) The active substances in the reference group
therapeutic group prevailing

group -------------------- ----------------------------------------------- ---------------------------------------------------------------------------------------------------------
1 Drugs for treatment of gastroduodenal 1/1 pharmaceuticals for the treatment of gastroduodenal ulcer and A02BA01 cimetidine
peptic ulcer disease and reflux oesophageal reflux disease, oral - H2 A02BA02 ranitidine
oesophageal disease receptors A02BA03 famotidine
1/2 of a medicament for the treatment of gastroduodenal ulcers and A02BA01 cimetidine
gastroesophageal reflux disease, parenteral - H2 A02BA02 ranitidine
A02BA03 receptor famotidine
1/3 of a medicament for the treatment of gastroduodenal ulcers and A02BC01 omeprazole of 10mg per
gastroesophageal reflux disease, after - inhibitors of proton tob.,
pumps and other drugs A02BC02 pantoprazole
A02BC03 lansoprazole,
A02BC04 rabeprazole, esomeprazole A02BC05

1/4 of a medicament for the treatment of gastroduodenal ulcers and A02BC01 omeprazole
gastroesophageal reflux disease, parenteral - A02BC02 inhibitor pantoprazole,
Proton pump A02BC05 esomeprazole -------------------------------------------
------------------------ ---------------------------------------------------------------------------------------------------------
Antispasmodics 2 2/1 antispasmodics, after A03AA04 mebeverine,
A03AB06 otilonium bromide
A03AD02 drotaverine,
A03BB01 butyl scopolamine
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
3 3/1 Prokinetics prokinetic after A03F itopride,
A03FA01 metoclopramide
A03FA03 domperidone
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
4 4/1 antiemetics Antiemetics after - SETRON after A04AA01 ondansetron,
A04AA02 granisetron,
A04AA05 palonosetron
4.2 antiemetics, SETRON, parenteral and rectal cancer. Applications - A04AA01 ondansetron,
A04AA02 granisetron,
A04AA05 palonosetron
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
5 Drugs for the treatment of inflammatory 01.05 medicament to treat inflammatory bowel disease, A07EC01 sulfasalazine,
intestinal diseases after - amino salicylic acid and its compounds similar A07EC02 mesalazine
----------------------------------- -------------------------------- ---------------------------------------------------------------------------------------------------------

7 7/1 multienzyme preparations multienzyme preparations, after - micronized drug A09AA02 multienzyme preparations -
micronised form of the dosage form over 20,000 U
in one tablet
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
8 Drugs in the treatment of diabetes - 8/1 krátkodoběpůsobící insulins, human insulin cartridges A10AB01,
A10AB04 insulins, insulin lispro
A10AB05 insulin aspart
A10AB06 insulin glulisine
8/2 dlouhodoběpůsobící A10AE04 insulin glargine
A10AE05 insulin, insulin detemir
8/3 insulins, human insulin vials A10AB01
A10AB04 insulin lispro
A10AB05 insulin aspart
A10AB06 insulin glulisine
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
9 Drugs for the treatment of diabetes 9/2 blood glucose lowering drugs, after - A10BB07 sulphonylurea glipizide, A10BB08 gliquidone,
II. Generation A10BB09 gliclazide,
A10BB12 glimepiride
9/4 of a medicament for the treatment of diabetes, after - glinides A10BX02 repaglinide,
A10BX03 nateglinide
9/5 blood glucose lowering drugs, drugs affecting A10BH01 sitagliptin
incretin system A10BH02 vildagliptin, A10BH03
saxagliptin,
A10BX04 exenatide,
A10BX07 liraglutide
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
10 Drugs for treatment of deficiency 1.10 medicament for the treatment of deficiency of minerals after - salt A12AA04 calcium carbonate,
minerals after A12AA07 calcium chloride, calcium
2.10 medicament for the treatment of deficiency of minerals after - lactate salt A12CC06 magnesium
magnesium A12CC30 magnesium, various salts in combination
--------------------------------------- ---------------------------- ---------------------------------------------------------------------------------------------------------
11 Enzymes for long-term enzyme replacement 11/1 to long-term replacement therapy with agalsidase alfa hereditary A16AB03,
treatment of inherited disorders of lipid metabolism disorders A16AB04 agalsidase beta
lipid metabolism
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
12 Drugs for the treatment or prophylaxis of 1/12 of a medicament for the therapy or prophylaxis of thromboembolic B01AB04 dalteparin,
thromboembolic disease disease, parenteral - low molecular weight heparins - B01AB05 enoxaparin
lower sílyurčené especially for prophylaxis TEN B01AB06 nadroparin,
B01AB08 reviparin,
B01AB12 bemiparin
2.12 medicament for the therapy or prophylaxis of thromboembolic B01AB04 dalteparin,
disease, parenteral - low molecular weight heparins - B01AB05 enoxaparin
higher sílyurčené primarily for the treatment of TEN B01AB06 nadroparin,
B01AB08 reviparin,
B01AB12 bemiparin
3.12 medicament for the therapy or prophylaxis of thromboembolic B01AE01 desirudin,
disease, parenteral - direct inhibitors of factor Xa B01AE02 lepirudin,
B01AE06 bivalirudin and thrombin -------------------------------------------
------------------------ ---------------------------------------------------------------------------------------------------------

13 Drugs for the treatment or prophylaxis of 1/13 of a medicament for the therapy or prophylaxis of thromboembolic B01AC04 clopidogrel,
thromboembolic disease condition after - ties antagonists ADP receptor B01AC22 prasugrel
2.13 medicament for the therapy or prophylaxis of thromboembolic B01AE07 dabigatran
disease, after - the direct inhibitors of factor Xa and B01AX06 rivaroxaban,
Thrombin B01A apixaban
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
14 Specific drug therapy 14.2 specifickáléčiva the treatment of pulmonary arterial C02KX01 bosentan,
pulmonary arterial hypertension, hypertension (PAH), after C02KX02 ambrisentan
(PAH)
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
15 fibrinolytic fibrinolytic 1.15 parenteral, parenteral - enzymes B01AD02 alteplase,
B01AD04 urokinase,
B01AD11 tenecteplase
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
16 Antifibrinolytic agents - amino acids 16/1 antifibrinolytic after - B02AA02 amino acid, tranexamic
B02AA03 acid aminomethylbenzoic
16/2 antifibrinolytic parenteral - B02AA02 amino acid, tranexamic
B02AA03 acid aminomethylbenzoic
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
17 Drugs for treatment of anemia (salt 1.17 medicament for the treatment of anemia, after - double. B03AA02 or trivalent iron fumarate, iron
) iron B03AA07 ferrous sulfate,
B03AB02 iron complex with isomaltose
2.17 medicament for the treatment of anemia, parenteral - B03AC02 trivalent iron complex with isomalt,
B03AC07 iron gluconate, sodium ferric
B03AC carboxymaltosum ferricum
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
18 Factors erythropoiesis stimulating erythropoiesis stimulating factors 18.01, parenteral B03XA01 erythropoietin (epoetin alfa)
acting at a receptor B03XA02 darbepoetin alfa
Erythropoietin B03XA03 pegepoetin (
Methoxy polyethylene glycol-epoetin beta)
epoetin beta,
epoetin delta,
epoetin zeta
NO donors for therapy of angina 20.01 NO donors for therapy of angina pectoris - therapy C01DA02 glyceryl trinitrate,
--------------------------- ---------------------------------------- ---------------------------------------------------------------------------------------------------------
20 pectoris acute attack, sublingual. Isosorbide dinitrate C01DA08
20/2 NO donors for therapy of angina pectoris - isosorbide dinitrate long C01DA08,
therapy, after C01DA14 isosorbide mononitrate,
C01DX12 molsidomine
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
21 Antihypertensive agents working 21/1 antiadrenergic central and peripheral C02AC05 moxonodine,
addition of prazosin, after C02AC06 rilmenidine,
C02CA06 urapidil
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
22 22.1 Diuretics diuretics, hydrochlorothiazide after C03AA03,
C03B metipamide,
C03BA04 chlorthalidone,
C03BA11 indapamide

----------------------------------------------- -------------------- ---------------------------------------------------------------------------------------------------------
23 Antihypertensive drugs (beta-blockers) 1.23 antihypertensives, beta blockers cardioselective - C07AB02 metoprolol (non-sustained
neratardované, and short-acting, after the dosage form)
C07AB03 atenolol,
C07AA17 bopindolol
2.23 antihypertensives, beta blockers cardioselective - C07AB02 metoprolol (controlled release dosage
retarded, and long-acting forms after)
C07AB04 acebutol,
C07AB05 betaxolol,
C07AB07 bisoprolol,
C07AB08 celiprolol,
C07AB12 nebivolol
C07AG02 carvedilol
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
24 Antihypertensive 24/1 blockers antihypertensives, the calcium channel blocker amlodipine C08CA01,
calcium channel dihydropyridine type, long-acting, after C08CA02 felodipine (retarded dosage forms
)
C08CA03 isradipine (sustained release dosage forms
)
C08CA08 nitrendipine,
C08CA09 lacidipine
C08CA10 nilvadipine,
C08CA12 barnidipine,
C08CA12 lercanidipine
24/2 antihypertensives, calcium channel blockers verapamil C08DA01,
fenylalkylaminového and benzothiazepine type after, C08DB01 diltiazem
retard forms
24/3 antihypertensives, calcium channel blockers verapamil C08DA01,
fenylalkylaminového and benzothiazepine type after, C08DB01 diltiazem
krátkodoběpůsobící
---------------------------------------------- --------------------- ---------------------------------------------------------------------------------------------------------
25 Antihypertenziva- drugs which 25/1 antihypertensives, ACE inhibitors - short and C09AA01 captopril,
on the renin-angiotensin-intermediate-acting, after C09AA02 enalapril,
Aldosterone C09AA06 quinapril
2.25 antihypertensives, ACE inhibitors, long-acting, C09AA03 lisinopril,
After C09AA04 perindopril, ramipril C09AA05,
C09AA08 cilazapril,
C09AA09 fosinopril,
C09AA10 trandolapril, C09AA11
spirapril,
C09AA13 moexipril,
C09AA16 imidapril
25/3 antihypertensives, angiotensin II antagonists alone, C09CA01 losartan,
After C09CA02 eprosartan,
C09CA03 valsartan,
C09CA04 ibersartan,
C09CA06 candesartan,
C09CA07 telmisartan,
C09CA08 olmesartan
25/4 antihypertensives, aldosterone antagonists, after C03DA01 spironolactone,
C03DA04 eplerenone
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
26 Peripheral vasodilators Peripheral vasodilators 26/2, parenteral C04AB02 tolazoline,
C04AD etofylin,
C04AD03 pentoxifylline
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
28 hypolipidemics 28.01 lipid lowering drugs, statins, simvastatin after C10AA01,
C10AA02 lovastatin,
C10AA03 pravastatin,
C10AA04 fluvastatin
C10AA05 atorvastatin,
C10AA07 rosuvastatin
28/2 lipid lowering drugs - fibrates bezafibrate after C10AB02,

C10AB05 fenofibrate,
C10AB08 ciprofibrate
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
29 Antifungals used in 29/1 antifungal agents used in dermatology for local D01AA01 Nystatin,
dermatology therapy (except triethanolamine dodecylbenzensulfonas and D01AA02 natamycin
tridecanamini undecylenas) D01AC01 clotrimazole,
D01AC03 econazole,
D01AC10 bifonazole,
D01AC11 oxiconazole,
D01AC16 flutrimazole,
D01AE14 ciclopirox,
D01AE15 terbinafine
D01AE22 naftifine
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
30 antipsoriatic used in 30/1 antipsoriatic used in dermatology for local D05AA tar
dermatology therapy D05AA tar tar (tar discolored)
30/2 antipsoriatic used in dermatology for local D05AX02 calcipotriol,
therapy, other drugs than tar D05AX03 calcitriol,
D05AX04 tacalcitol,
D05AX05 tazarotene
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
31 Antibiotics used for topical 31/1 antibiotics used for local therapy D06AX01 fusidic acid,
Therapy D06AX13 retapamulin

----------------------------------------------- -------------------- ---------------------------------------------------------------------------------------------------------
32 Corticosteroids used to 32/1 corticosteroids used for local therapy - weak and D07AB19 dexamethasone acetate (0.01%)
local therapy - weak and moderate moderate 1st and 2nd generation D07AC04 fluocinolone acetonide (0.01%)
strong D07AA02 hydrocortisone acetate (1.0%)
D07AA03 prednisolone (0.4%)
D07AB09 triamcinolone acetonide (0.1%)
D07AB19 dexamethasone acetate 0.025%
D07AC04 fluocinolone acetonide 0.025%
32/2 corticosteroids used for local therapy - weak and D07AB10 alclomethason (0.05%)
moderate 3rd and 4th generation D07AB08 desonide,
D07AB02 hydrocortisone butyrate (0.1%)
-------------------------------------- ----------------------------- ---------------------------------------------------------------------------------------------------------
33 Corticosteroids used to 33/1 corticosteroids used for local therapy - strong and D07AC04 fluocinolone acetonide (0.05% -
local therapy - very strong and very strong first and second generation 0.2%)
Strong D07AC03 desoximethason (0.25)
33/2 corticosteroids used for topical therapy - strong and D07AC01 betamethasone valerate (0.1%)
very strong 3rd and 4th generation D07AC01 betamethasone dipropionate
(0.05%)
D07AC17 fluticasone propionate (0.05%)
D07AC12 halometasone propionate (0.05%)
D07AD02 halcinonide (0.1%)
D07AD01 clobetasol propionate (0.05%)
D07AC14 methylprednisolone aceponate
(0.1%)
D07AC13 mometasone furoate (0.1%)
D07AC18 Prednicarbat
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
35 Drugs used for 35/1 topical drugs used for topical treatment of acne vulgaris - D10AD01 tretinoin,
treatment of acne vulgaris D10AD03 retinoid adapalene
D10AD04 isotretinoin
35/2 drugs used for topical treatment of acne vulgaris - D10AE01 benzoyl peroxide,

Other substances D10AX03 azelaic acid
35/3 drugs used for topical treatment of acne vulgaris - D10AF01 clindamycin
D10AF02 erythromycin antibiotic substances -------------------------------------------
------------------------ ---------------------------------------------------------------------------------------------------------
36 immunomodulators used for 36/1 immunomodulators used for topical treatment of atopic D11AX14 tacrolimus
topical treatment of atopic dermatitis D11AX15 pimecrolimus

dermatitis ---------------------------------------------- --------------------- ---------------------------------------------------------------------------------------------------------
37 gynecological antifungals 37/1 gynecological antifungals, topical or vaginal G01AF02 clotrimazole,
Applications G01AF05 econazole,
G01AF12 fenticonazole
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
38 Androgens 38/1 androgens to testosterone replacement therapy G03BA03,
G03BB01 mesterolone
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
39 Gynecological Gynecological 39/1 antibiotics antibiotics, topical or vaginal G01AA02 natamycin
used for local therapy applications G01AA10 clindamycin
G01AX12 ciclopirox
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
40/1 40 Prostaglandins Prostaglandins, parenteral G02AD01 dinoprost
G02AD04 carboprost
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
41 prolactin inhibitors 41/2 inhibitoryprolaktinu, dopaminergic agonists II. G02CB03 cabergoline
Generation G02CB04 quinagolide
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
42 Estrogens 42/1 estrogens, estradiol after G03CA03,
G03CA04 estriol,
G03DC05 tibolone
42/2 estrogens, topical or vaginal application G03CA03 oestradiol
G03CA04 estriol
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
43 progestins 43/1 progestinyI. generation after G03DA02 medroxyprogesterone,
G03DC02 norethindrone,
G03DC03 lynestrenol
43/2 progestinyII. generation after G03DA04 progesterone,
G03DB01 dihydrogesterone
43/3 progestins, parenteral G03DA03 hydroxyprogesterone,
G03DA04 progesterone (depot dosage forms
)
------------------------------------- ------------------------------ ---------------------------------------------------------------------------------------------------------
44 Gonadotropins chorionic gonadotropin 44/1, parenteral G03GA01 chorionic gonadotropin,
G03GA08 recombinant chorionic
gonadotropin
44/2 gonadotropins other parenteral G03GA02 human gonadotropin,
human gonadotropin highly purified,
G03GA04 urofolitropin,
G03GA04 urofolitropin highly purified,
G03GA05folitropin alpha
G03GA06 follitropin beta,
G03FA07 lutropin alfa

----------------------------------------------- -------------------- ---------------------------------------------------------------------------------------------------------
45 Urinary antispasmodics Urinary antispasmodics 45/1, non-sustained form, after G04BD04 oxybutynin,
G04BD06 propiverin,
G04BD07 tolterodine
G06BD09 trospium chloride
45/2 urinary antispasmodics, retard forms, and after G04BD04 oxybutynin,
transdermal G04BD07 tolterodine
G04BD08 solifenacin,
G04BD10 darifenacin
G04BD11 fesoterodine
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
46 Drugs for the treatment of benign 46/1 pharmaceuticals for the treatment of benign prostatic hyperplasia, C02CA04 doxazosin,
prostatic hyperplasia alpha adrenergic receptor antagonists, after G04CA01 alfuzosin,
G04CA02 tamsulosin,
G04CA03 terazosin
46/2 medicament for the treatment of benign prostatic hyperplasia G04CB01 finasteride,
Others, after G04CB02 dutasteride
G04CX03 mepartricin
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
47 antagonists of growth hormone 47/2 antagonists, growth hormone, long-acting, HB1CB02 octreotide,
Parenteral H01CB03 lanreotide
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
48 antagonists gonadotropin 48/1 antagonists -uvolňujícího gonadotropin hormone, ganirelix H01CC01,
releasing hormone parenteral H01CC02 cetrorelix
------------------------------------------ ------------------------- ---------------------------------------------------------------------------------------------------------
49 Corticosteroids for systemic corticosteroids 49/1 with predominantly glucocorticoid methylprednisolone H02BA04,
therapy effect after H02AB07 prednisone,
H02AB08 triamcinolone
49/2 corticosteroids with predominantly glucocorticoid H02AB01 betamethasone (depot formulation
effect, parenteral - depots)
H02AB04 methylprednisolone (
depot formulations)
------------------------------------- ------------------------------ ---------------------------------------------------------------------------------------------------------
50 antithyroid drugs 50/1 antithyroid drug propylthiouracil after H03BA02,
H03BB02 thiamazole
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
51/1 51 Tetracyclines tetracyclines, doxycycline after J01AA02,
J01AA08 minocycline
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
52 narrow-spectrum penicillin with 52/1 penicilinys narrow spectrum, after J01CE02 Phenoxymethylpeni-,
J01CE06 penamecilin,
J01CE10 Benzathine phenoxymethylpenicillin
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
53/1 53 Cephalosporins cephalosporins of first generation, after J01DB01 cephalexin,
J01DB05 cefadroxil,
J01DC04 cefaclor
53/2 cephalosporins II. generation after J01DC02 cefuroxime axetil,
J01DC10 cefprozil
53/3 I. generation cephalosporins, parenteral J01DB03 cephalothin,
J01DB04 cefazolin

53/4 cephalosporins III. generation (except cefoperazone) J01DD01 cefotaxime,
J01DD04 parenteral ceftriaxone
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
54 carbapenems 54/1 carbapenems, parent, J01DH02 meropenem,
J01DH04 doripenem,
J01DH51 imipenem and enzyme inhibitor

----------------------------------------------- -------------------- ---------------------------------------------------------------------------------------------------------
55 macrolide, azalide, 55/1 macrolides after J01FA01 erythromycin,
ketolide and lincosamide J01FA02 spiramycin
J01FA06 antibiotics roxithromycin,
J01FA09 clarithromycin
J01FA10 azithromycin
55/2 lincosamides, after J01FF01 clindamycin
J01FF02 Lincomicyn
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
56 Quinolones 56/1 quinolones after (except moxifloxacin, norfloxacin) J01MA01 ofloxacin
J01MA02 ciprofloxacin,
J01MA03 pefloxacin,
J01MA12 levofloxacin
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
57 Imidazole derivatives 57/1 imidazole derivatives after J01XD01 metronidazole
J01XD03 ornidazole
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
58 Antifungals for systemic therapy 58/1 antifungals for systemic therapy after - triazole J02AC03 voriconazole,
Derivatives J02AC04 posaconazole
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
59 System antivirals against 59/1 systemic antiviral drugs against infections caused J05AB01 aciclovir
herpesvirus infections caused by the herpes virus hominis, after J05AB09 famciclovir
hominis J05AB11 valaciclovir,
J05AB15 brivudine
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
60 Antiretroviral agents 60/2 antiretroviral nucleoside and nucleotide J05AF08 adefovir,
inhibitoryreverzní transcriptase, only for HBV J05AF10 entecavir
infection after
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
61 Neuraminidase inhibitors 61/1 inhibitoryneuraminidázy after injections and inhalation J05AH01 zanamivir,
J05AH02 oseltamivir
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
62 Immunoglobulins 62/1 normal human immunoglobulins, normal human, im J06BA01 normal human immunoglobulins
intramuscular injection
62/2 normal human immunoglobulins, sc J06BA01 normal human immunoglobulins
for subcutaneous administration
62/3 normal human immunoglobulins, also J06BA02 normal human immunoglobulins
for intravenous administration
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
Taxanes 63 63/1 taxanes paclitaxel parenteral L01CD01,
L01CD02 docetaxel

----------------------------------------------- -------------------- ---------------------------------------------------------------------------------------------------------
65 super-super-active analogues gonadotropin- 65/1 analogues of gonadotropin-releasing hormone, leuprolide L02AE02,
releasing hormone parenteral L02AE03 goserelin,
L02AE04 triptorelin
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
66 Antiestrogens inhibitors 66/1 antiestrogens tamoxifen after L02BA01,
Aromatase L02AB02 toremifene
66/2 inhibitoryaromatáz after L02BG03 anastrozole
L02BG04 letrozole,
L02BG06 exemestane
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
67 Antiandrogens 67/1 antiandrogens (except bicalutamide 150mg) after L02BB01 flutamide,
L02BB03 bicalutamide
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
69 Interferons and other drugs 69/1 alpha interferons for the treatment of selected L03AB01 natural interferon alpha,
cancer, parenteral -nepegylované L03AB04 interferon alfa-2a,
forms L03AB05 interferon alfa-2b
69/2 interferon alpha-2- pegylated forms, parenteral L03AB11 peginterferon alfa-2a,
L03AB10 peginterferon alfa-2b
69/3 interferons and other drugs for the treatment of multiple L03AB07 interferon beta-1a,
sclerosis, parenteral L03AB08 interferon beta-1b,
L03AX13 glatiramer acetate,

----------------------------------------------- -------------------- ---------------------------------------------------------------------------------------------------------
70 Immunosuppressive 70/1 immunosuppressants - mTOR inhibitor, sirolimus after L04AA10,
L04AA18 everolimus
70/2 immunosuppressants - biological pharmaceuticals for the treatment L04AA11 etanercept,
rheumatic, skin or bowel disease, L04AA12 infliximab,
Parenteral L04AA17 adalimumab
L04AB05 certolizumab pegol-
L04AB06 golimumab
Immunosuppressive 70/3 - biological pharmaceuticals for the treatment L04AA24 Abatacept,
rheumatic, skin or bowel disease, L04AC07 tocilizumab
Special parenteral
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
71 NSAIDs 71/1 NSAIDs - non-selective, after M01AB05 diclofenac,
M01AC05 lornoxicam,
M01AC06 meloxicam,
M01AE01 ibuprofen,
M01AE02 naproxen,
M01AE03 ketoprofen,
M01AE11 tiaprofenic acid,
M01AE12 oxaprozin,
M01AE17 Dexketoprofen,
M01AG02 tolfenamic acid,
M01AX01 nabumetone,
M01AX17 nimesulide
71/2 NSAIDs rectum. Applications M01AB01 indomethacin,
M01AB05 diclofenac,
M01AC06 meloxicam,
M01AE01 ibuprofen,
M01AE03 ketoprofen
71/3 NSAIDs, diclofenac parenteral M01AB05,
M01AC01 piroxicam, lornoxicam M01AC05,
M01AC06 meloxicam,
M01AE03 ketoprofen,
M01AH04 parecoxib
71/4 NSAIDs, COX 2 selective M01AH01 celecoxib,

(Coxibs) after M01AH03 valdecoxib,
M01AH05 etoricoxib
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
73 centrally acting muscle relaxants 73/1 centrally acting muscle relaxants, tolperisone after M03BX04,
M03BX05 thiocolchicoside,
N05BX01 mefenoxalon,
M03BX01 baclofen,
M03BX02 tizanidine,
M03BX07 tetrazepam
73/2 centrally acting muscle relaxants, tolperisone parenteral M03BX04,
M03BX05 thiocolchicoside
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
74 Drugs for the treatment and prophylaxis 74/1 pharmaceuticals for the treatment and prophylaxis of osteoporosis - vitamin D, ergocalciferol A11CC01,
osteoporosis after A11CC05 cholecalciferol
74/2 pharmaceuticals for the treatment and prophylaxis of osteoporosis - metabolites A11CC03 alfacalcidol,
vitamin D, calcitriol after A11CC04
74/3 medicament for the therapy and prophylaxis of osteoporosis, after - M05BA04 alendronic acid,
bisphosphonates M05BA06 ibandronic acid,
M05BA07 acid, risedronic
M05BB03 acid aledronová with vit. D3
74/4 pharmaceuticals for the treatment and prophylaxis of osteoporosis - H05AA02 hormone, teriparatide,
parathyroid and analogues. Parenteral H05AA03 parathormon
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
75 Drugs for the treatment of hypercalcemia 75/1 pharmaceuticals for the treatment of hypercalcemia and / or osteolysis at M05BA02 acid clodronic
and / or osteolysis in malignant malignant diseases, parenteral M05BA03 pamidronic acid,
M05BA06 disease ibandronic acid,
M05BA08 zoledronic acid
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
76 Antineuropatická medicament 76/1 antineuropatická medicament for the local treatment of peripheral N01BB02 lidocaine,
neuropathic pain N01BX04 capsaicin -------------------------------------------
------------------------ ---------------------------------------------------------------------------------------------------------
77 Local anesthetics 77/1 anestetikalokální, parenteral administration N01BB trimecaine,
N01BB01 bupivacaine,
N01BB09 ropivacaine,
N01BB10 levobupivacaine
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
78 Opioids 78/1 strong opioid, hydromorphone after N02AA03,
N02AA05 oxycodone
78/2 strong opioids, Transderm. Applications N02AB03 fentanyl,
N02AE01 buprenorphine
78/3 weak opioids, after N02AA08 dihydrocodeine,
N02AX02 Tramadol
78/4 strong opioids for the treatment of breakthrough pain N02AA01 morphine
N01AH01 fentanyl
78/5 strong opioid anesthesia, parenteral N01AH01 fentanyl,
N01AH02 alfentanyl,
N01AH03 sufentanyl,
N01AH06 remifentanyl
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
79 Analgesics-antipyretics 79/1 analgesic-antipyretics, after N02BA01 acetylsalicylic acid,
N02BA02 aloxiprin,
N02BE01 paracetamol

79/2 analgesic-antipyretic parenteral N02BB02 Metamizole
N02BE01 paracetamol
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
80 antimigrenics the treatment of acute 80/1 antimigrenics for treatment of acute attack, after - N02CC01 sumatriptan,
selektivníagonisté seizure of serotonin N02CC02 naratriptan,
N02CC03 zolmitriptan,
N02CC06 eletriptan,
N02CC07 frovatriptan
80/2 antimigrenics for treatment of acute attack, nasal. N02CC01 sumatriptan,
Applications -selective serotonin agonists zolmitriptan N02CC03
---------------------------------------- --------------------------- ---------------------------------------------------------------------------------------------------------
82 Anti-Parkinson 82/1 antiparkinson-anticholinergic biperiden after N04AA02,
N04AA04 Procyclidine,
N04AC01 benzatropine
82/2 antiparkinson agents, dopamine agonists, after N04BC04 ropinirole,
N04BC05 pramipexole
82/3 antiparkinsonics, COMT inhibitors, tolcapone after N04BX01,
N04BX02 entacapone
82/4 antiparkinsonics, MAO inhibitors, after N04BD01 selegiline
N04BD02 rasagiline
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
83 Antipsychotics - 83/1 neuroleptic antipsychotics - neuroleptics classical class I, after N05AA01 chlorpromazine,
N05AF03 chlorprothixene,
N05AF05 zuklopentixol
83/2 antipsychotics - neuroleptics classic, II. Class N05AD01 haloperidol,
After N05AF01 flupentixol
83/3 antipsychotic-neuroleptic, parenteral - nedepotní N05AA01 chlorpromazine,
N05AA02 levomepromazine,
N05AD01 haloperidol,
N05AF05 zuklopentixol
83/5 antipsychotics - neuroleptics II. Class N05AD01 parenteral haloperidol,
- N05AF01 depot flupentixol
N05AF05 zuklopentixol
83/6 antipsychotics with a low antipsychotic potential, N05AD03 melperon,
After N05AL03 tiaprid
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
84 Antipsychotika- II. 84/1 generation antipsychotics - serotonin antagonists and N05AX08 Risperidone,
N05AX13 dopamine receptors, paliperidone,
N05AE03 sertindole, ziprasidone N05AE04

84/2 antipsychotics - multireceptoroví antagonists N05AH03 olanzapine, quetiapine N05AH04,
N05AX11 zotepine
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
85/1 85 Anxiolytics anxiolytics, after - N05BA01 benzodiazepine diazepam,
N05BA02 chlordiazepoxide
N05BA03 medazepam,
N05BA04 oxazepam,
N05BA08 bromazepam,
N05BA12 alprazolam,
N05BA23 tofisopam
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
86 Antidepressants Antidepressants 86/1, after - not selectively acting inhibitors N06AA02 imipramine,
monoamine reuptake N06AA04 clomipramine,
N06AA08 dibenzepin, N06AA09
amitriptiline,
N06AA10 nortriptyline,
N06AA16 Dosulepin,
N06AA21 maprotiline
N06AX03 mianserin

86/2 antidepressants after - selective serotonin reuptake N06AB03 fluoxetine,
monoamine neurotransmitters acting on one system N06AB04 citalopram,
(SSRI, NARI, SARI); - Reversible inhibitors N06AB05 paroxetine,
monoamine oxidase (RIMA); - Reuptake enhancer N06AB06 sertraline,
Serotonin (SRE) N06AB08 fluvoxamine,
N06AB10 escitalopram,
N06AX05 trazodone
N06AX14 tianeptine
86/3 antidepressants after - selective serotonin reuptake N06AX16 Venlafaxine,
monoamines a transmitter operating on two systems (SNRI, milnacipran N06AX17,
NASS, DNRI) N06AX11 Mirtazapine
-------------------------- ----------------------------------------- ---------------------------------------------------------------------------------------------------------
87 Drugs for treatment of dementia 87/1 medicament for the treatment of Alzheimer's disease, and after N06DA02 donepezil,
Alzheimer's type transdermal N06DA03 rivastigmine,
N06DA04 galantamine,
N06DX01 memantine
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
88-depressants 88/2 nootropics, parenteral N06BX03 piracetam,
N06BX18 vinpocetine
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
89 Parasympathomimetics 89/1 parasympathomimetics after (except distigminu) N07AA01 neostigmine,
N07AA30 ambenonium
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
90 Drugs for topical therapy and 90/1 drugs used for topical therapy and prophylaxis R01AD01 beclomethasone,
prophylaxis of allergic rhinitis allergic rhinitis - intranasal corticosteroids R01AD05 budesonide, mometasone R01AD06,
Applications R01AD08 fluticasone,
R01AD12 fluticasone furoate
90/2 drugs used for topical therapy and prophylaxis R01AC02 levocabastine,
Allergic rhinitis - intranasal antihistamine azelastine R01AC03

application ---------------------------------------------- --------------------- ---------------------------------------------------------------------------------------------------------
91 reliever drugs for the treatment of asthma 91/1 medicines used in the treatment of asthma reliever after R03CC02 salbutamol,
R03CC08 procaterol,
R03CC13 clenbuterol
91/2 drugs used for reliever therapy for asthma, inhaled salbutamol R03AC02,
Applications R03AC03 terbutaline,
R03AC04 terbutaline

----------------------------------------------- -------------------- ---------------------------------------------------------------------------------------------------------
92 Preventive antiastmatika- 92/1 preventive antiastmatika- corticosteroids such as budesonide R03BA02,
corticosteroid aerosols, suspensions and solutions for inhalation R03BA05 fluticasone,
R03BA08 ciclesonide
92/2 preventive antiasthmatics -kortikosteroidy, powders, R03BA02 budesonide,
R03BA05 inhaled application of fluticasone -------------------------------------------
------------------------ ---------------------------------------------------------------------------------------------------------
93 Preventive asthma medications 93/1 preventive asthma medication from a long R03AC12 salmeterol,
acting beta-agonists, inhaled formoterol applications R03AC13
93/2 preventive asthma medication, after - R03DA04 xanthines theophylline (sustained release dosage forms
)

R03DA05 aminophylline (sustained release dosage forms
)
93/3 preventive asthma medication, after - leukotriene modifiers R03DC01 zafirlukast,
R03DC03 montelukast
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
94 expectorants 94/2 expectorants, parenteral and inhalation R05CB01 acetylcysteine,
R05CB02 bromhexine,
R05CB03 carbocysteine,
R05CB05 mesna,
R05CB06 ambroxol
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
95 Antitussives 95/1 antitussives, after (except codeine) R05DA01 ethylmorphine,
R05DB13 butamirát,
R05DB19 dropropizine,
R05DB27 levodropropizine
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
96 Antihistamines for systemic 96/1 sedative antihistamines, after R06AA04 clemastine,
application R06AB03 dimetindene,
R06AX bisulepine,
R06AX02 cyproheptadine,
RR06AX17 ketotifen
96/2 non-sedating antihistamine, cetirizine after R06AE07,
R06AE09 levocetirizine
R06AX13 loratadine
R06AX26 fexofenadine,
R06AX27 desloratadine,
R06AX29 bilastine
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
97 Ophthalmological - 97/1 ophthalmologicals anti-infectives, anti-infectives - quinolones, ofloxacin local S01AX11,
S01AX13 ciprofloxacin,
S01AX17 lomefloxacin,
S01AX19 levofloxacin
S01AX22 moxifloxacin
97/2 ophthalmologicals, anti-infectives - other antibiotics, chloramphenicol S01AA01,
S01AA11 local gentamicin,
S01AA12 tobramycin
S01AA13 ACIDUM fusidicum,
S01AA23 netilmicin
S01AA24 kanamycin,
S01AA30 combination of different antibiotics -
neomycin / bacitracin, S01AB04
sulfacetamide
97/3 ophthalmologicals - anti-infectives - Antivirals, local S01AD03 aciclovir
S01AD09 ganciclovir
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
98 Ophthalmological - corticosteroids 98/1 ophthalmologicals - First series of corticosteroids, topical dexamethasone S01BA01,
S01BA02 hydrocortisone
98/2 ophthalmologicals - second row corticosteroids, topical cortisone S01BA03,
S01BA04 prednisolone,
S01BA07 fluorometholone
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
99 Ophthalmological - inflammatory 99/1 ophthalmologicals - inflammatory drugs, local S01BC01 indomethacin,
S01BC03 drug diclofenac
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
100 Ophthalmological used for therapy 100/1 ophthalmologicals used for the treatment of glaucoma - S01EA04 clonidine,
Glaucoma sympathomimetic or parasympathomimetic, local S01EA05 brimonidine
S01EB01 pilocarpine
100/2 ophthalmologicals used for therapy of glaucoma - S01EC03 dorzolamide,
inhibitorykarboanhydrázy, local S01EC04 brinzolamide
100/3 ophthalmologicals for the treatment of glaucoma - beta-blocker, timolol S01ED01,

local S01ED02 betaxolol,
S01ED03 levobunolol,
S01ED05 carteolol
100/4 ophthalmologicals used for therapy of glaucoma - S01EE01 latanoprost
prostaglandins or derivatives thereof, a local S01EE02 unoprostone,
S01EE03 bimatoprost,
S01EE04 travoprost
S01EE05 tafluprost
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
101 Ophtalmologika - other ophtalmologika 101/1 - S01XA iodide, potassium iodide-sodium
S01XA04 potassium iodide
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
102 Ophthalmological - Antialergics 102/1 ophthalmologicals - Antialergics S01GA52 tetryzolin combination
(Except corticosteroids) S01GX01 acid kromoglyková,
S01GX02 levocabastine, S01GX03 acid
spaglumová,
S01GX05 Lodoxamide,
S01GX06 emedastine,
S01GX07 azelastine
S01GX08 ketotifen,
S01GX09 olopatadine, S01GX10 epinastine
------------------------------------------ ------------------------- ---------------------------------------------------------------------------------------------------------
103 Anti-VEGF 103/1 protilátkyanti-VEGF in ophthalmology S01LA03 pegaptanib,
ophthalmology S01LA04 ranibizumab
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
104 Therapeutic allergen extracts 104/2 therapeutic allergen extract - standardized allergen extracts V01AA
injectors, oral
104/3 therapeutic allergen extract - standardized allergen extracts V01AA
injectors, sublingual
104/6 therapeutic allergen extract - standardized allergen extracts V01AA
injectable, aqueous
104/7 therapeutic allergen extract - standardized allergen extracts V01AA
injectable, depot
-------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
105 Tests for allergic diseases 105/1 assays for allergic diseases - intradermal V04CL assays for allergic diseases
105/2 tests for allergic diseases - skin prick tests V04CL tests for allergic diseases
-------------------------------- ----------------------------------- ---------------------------------------------------------------------------------------------------------
106 Drugs used for the treatment of 106/1 medicament for the treatment of hyperkalemia and hyperphosphatemia, after V03AE02 sevelamer V03AE03
hyperkalemia and hyperphosphatemia lanthankarbonát -------------------------------------------
------------------------ ---------------------------------------------------------------------------------------------------------
107 Nutrition for congenital disorders 107/1 definovanésměsi of amino acids phenylalanine V06CA1
metabolism (powder form for amino acid content)
107/2 definovanésměsi aminikyselin without phenylalanine V06CA2
with carbohydrates and fats for patients under 1 year of age
(Powder form for amino acid content)
107/3 definovanésměsi of amino acids phenylalanine for V06CA4
pregnant (powder form for amino acid content)
107/4 definovanésměsi of amino acids phenylalanine V06CA5
(Dosage forms of amino acid content)
107/5 definovanésměsi of amino acids phenylalanine V06DD11
(Dávkovanéformy liquid amino acid content)

107/6 defined mixture of essential amino acids for V06DD12
patients under 1 year of age with metabolic disorders
urea cycle (powder form to content
amino acids)
107/7 defined mixture of essential amino acids for V06DD13
pacientynad 1 year of age with impaired
urea cycle metabolism (powder form to
amino acid content)
107/8 defined mixtures of amino acids isoleucine, V06DD14
leucine and valine carbohydrates and fats
pacientydo 1 year of age - a complete baby
food (powdered form for amino acid content)
107/9 defined mixtures of amino acids isoleucine, V06DD15
leucine and valine for patients within one year
age (powder form for amino acid content)
107/10 defined mixtures of amino acids isoleucine, V06DD16
leucine and valine for patients over 1 year
age (powder form for amino acid content)
107/11 defined mixtures of amino acids isoleucine, V06DD17
methionine, threonine and valine for patients
with methylmalonic acid and propionic acidaemia in 1
Year Age (a powdered form to content
amino acids)
107/12 defined mixtures of amino acids isoleucine, V06DD18
methionine, threonine and valine for patients
with methylmalonic acid and propionic acidaemia over
1 year of age
(Powder form for amino acid content)
107/13 defined mixtures of amino acids leucine V06DD19
Patient
1 year of age
(Powder form for amino acid content)
107/14 defined mixtures of amino acids leucine V06DD20
for patients over 1 year of age
(Powder form for amino acid content)
107/15 defined mixtures of amino acids lysine and V06DD21
a reduced amount of tryptophan for patients
with glutaric
acidémiído 1 year of age
(Powder form for amino acid content)
107/16 definovanésměsi of amino acids lysine and V06DD22
reduced
amounts of tryptophan to patients
glatarovou acidaemia with over 1 year of age
(Powder form for amino acid content)
107/17 defined mixtures of amino acids methionine V06DD23
enriched with L-cystine to patients
homocystinuric to 1
the age
(Powder form for amino acid content)
107/18 defined mixtures of amino acids methionine V06DD26
enriched L-cystine patients
homocystinuric over 1 year of age
(Powder form for amino acid content)
107/19 defined mixtures of amino acids tyrosine and V06DD27
phenylalanine carbohydrates and fats
pacientydo 1 year of age
- A complete baby food
(Powder form for amino acid content)
107/20 defined mixtures of amino acids tyrosine and V06DD29
phenylalanine in patients 1 year of age

(Powder form for amino acid content)
107/21 defined mixtures of amino acids tyrosine and V06DD27
phenylalanine for patients over 1 year of age
(Powder form for amino acid content)
107/22 definovanésměsi amino acids including combinations V06DD29
peptides with a low phenylalanine
(Powder form for amino acid content)
---------------------------------------- --------------------------- ---------------------------------------------------------------------------------------------------------
108 Nutrition - Enteral Nutrition 108/1 polymer nutrition standard - in liquid form V06EA1
108/2 polymer nutrition standard - hypercaloric V06EB01
108/3 polymer nutrition standard - with the addition of fiber V06EB02,
isocaloric V06EB04
108/4 polymer nutrition standard - with the addition of fiber V06EB02,
hypercaloric V06EB04
108/5 polymer special nutrition - hypercaloric fat-free V06EB03
108/6 polymer special nutrition - hypercaloric to complement V06EB05,
protein or protein and fiber V06EB06
108/7 polymer special nutrition - which is intended for the treatment V06EB10
liver failure
108/8 polymer special diet - a complement protein V06EB11
arginine azinku
108/10 polymer special nutrition - diabetic V06EB08
108/11 polymer special nutrition - with the addition of MCT oil V06EB09
108/12 oligopeptide liquid nutrition V06EC1
108/13 thickeners V06EE1
------------------------------------------ ------------------------- ---------------------------------------------------------------------------------------------------------
109 diet - milk substitutes 109/1 milk substitutes containing cow's milk protein V06DF1
109/2 milk substitutes for milk protein hydrolyzate V06DF2
109/3 milk substitutes low lactose and dairy V06DF4
protein hydrolyzate
109/4 special baby food containing various V06DE

amino acids ---------------------------------------------- --------------------- ---------------------------------------------------------------------------------------------------------
110 RTG soluble low osmolar X-ray 110/1 soluble low osmolar iodixanol nefrotropní rtg- V08AB09,
nefrotropní X-ray contrast agents kontrastnílátky - nonionic - iodine concentration of 150 V08AB10 iomeprol
- Nonionic mg / ml, parenteral
110/2 soluble low osmolar X-ray nefrotropní rtg- V08AB04 Iopamidol
kontrastnílátky - nonionic - concentration of iodine 200 V08AB10 iomeprol
mg / ml, parenteral
110/3 soluble low osmolar X-ray nefrotropní rtg- V08AB02 iohexol
contrast agents - non-ionic - concentration of iodine 240 V08AB05 iopromide,
mg / mL parenteral V08AB07 ioversol
110/4 soluble low osmolar X-ray nefrotropní rtg- V08AB02 iohexol
kontrastnílátky - nonionic - concentration of iodine 300 V08AB04 Iopamidol
mg / ml, parenteral V08AB05 iopromide,
V08AB07 ioversol,
V08AB10 iomeprol,
V08AB11 iobitrodol
110/5 soluble low osmolar X-ray nefrotropní rtg- V08AB03 acid ioxagliková,
kontrastnílátky - nonionic - concentration of iodine 320 V08AB07 ioversol,

mg / ml iodixanol parenteral V08AB09
110/6 soluble low osmolar X-ray nefrotropní rtg- V08AB02 iohexol
kontrastnílátky - nonionic - concentration of iodine 350 V08AB07 ioversol,
mg / ml, parenteral V08AB10 iomeprol,
V08AB11 iobitridol
110/7 soluble low osmolar X-ray nefrotropní rtg- V08AB04 Iopamidol
kontrastnílátky - nonionic - concentration of iodine 370 V08AB05 iopromide
mg / ml, parenteral
------------------------------------------ ------------------------- ---------------------------------------------------------------------------------------------------------
111 Contrast agents for examination 111/1 kontrastnílátky for ultrasound, V08DA01 microparticles with albumin,
Ultrasonic parenteral V08DA05 sulfur hexafluoride
114 paramagnetic agents 114/1 paramagnetic gadolinium V08CA01 gadopentetic acid,
V08CA02 acid gadoterová,
V08CA03 gadodiamide,
V08CA04 gadoteridol
--------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------
_______________


*) Unless specified in the relevant reference group route, then to
a reference group includes all essentially
therapeutically interchangeable medicinal products with similar or close
efficacy and safety, and similar clinical use, irrespective of their journey
administration.